◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Nippon Chemiphar Co., Ltd. (4539) Financial History

Name: Nippon Chemiphar Co., Ltd. (4539) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

Nippon Chemiphar Co., Ltd. (4539) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Tokyo, Japan with about 878 employees. Its market capitalization is roughly JPY 6 billion. In the fiscal year ended 2026-03-31, 4539 reported JPY 33.1B in revenue and JPY 198M in net income.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally.

Interactive charts & full statements →

4539 Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	JPY 33.1B	JPY 32.6B	JPY 30.7B	JPY 31.6B	—
Gross Profit	JPY 8.4B	JPY 8.7B	JPY 7.7B	JPY 8.2B	—
Operating Income (EBIT)	JPY 180M	JPY 607M	(JPY 495M)	(JPY 241M)	—
Net Income	JPY 198M	JPY 294M	(JPY 180M)	JPY 339M	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4539 Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(JPY 182M)	(JPY 182M)	(JPY 182M)	(JPY 183M)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4539 Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	JPY 50.0B	JPY 49.9B	JPY 49.5B	JPY 48.6B	—
Total Liabilities	JPY 30.5B	JPY 30.7B	JPY 31.1B	JPY 30.0B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4539 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

0570 · China Traditional Chinese Medicine Holdings Co. Limited — $7 billion
2005 · SSY Group Limited — $7 billion
2575 · Xuanzhu Biopharmaceutical Co., Ltd. — $6 billion
6185 · CanSino Biologics Inc. — $6 billion
3613 · Beijing Tong Ren Tang Chinese Medicine Company Limited — $6 billion
INDV · Indivior Pharmaceuticals, Inc. — $5 billion
0719 · Shandong Xinhua Pharmaceutical Company Limited — $4 billion
CURA · Curaleaf Holdings, Inc. — $3 billion

← 4538 All “0-9” companies 4540 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.